We are engaged in the discovery, development, and commercialization of novel small molecule agents to address significant clinical unmet needs. We are also developing novel formulations of approved products whose safety and efficacy profiles are well characterized. Although distinct, both efforts seek to improve the care of patients suffering from serious diseases and impaired quality of life. Our therapeutic areas of focus are bacterial infections, metabolic disorders, and pain/inflammation.
Focus Therapeutic Areas
Bacterial infections:
The incidence of hospital acquired infections is growing as drug-resistant bacteria are becoming more difficult to treat. There are significant challenges in adequately treating infections caused by multi-drug resistant pathogens such as staphylococcus aureas, pseudomonas aeruginosa, and acinetobacter baumannii. The resultant infections are often serious and life-threatening. We are working to identify new approaches to treating these infections with products that have improved efficacy and tolerability profiles.
Metabolic Disorders:
Cardiovascular Disease is one of the leading causes of death globally. Many patients suffering from CVD are also afflicted with insulin resistance, type 2 diabetes, dyslipidemia, and obesity. While there are several treatment options for a few of these conditions, a need persists for effective and safe therapies that address insulin resistance, obesity, low HDL cholesterol and atherosclerosis. We have several programs targeting one or more of these disease conditions.
Pain/Inflammation:
The prevalence of chronic and acute pain is growing steadily as our population ages and diagnosis rates improve. Although there are a number of medications to treat chronic and acute pain, new treatments that are both safe and tolerable remain essential. We are developing products with improved efficacy and side effect profiles in several areas of acute and chronic pain.
